计算机化决策支持系统(CDSS)用于基层医疗尿路感染抗菌药物耐药性监测
研究利用法国CDSS中2017至2020年提交的尿路感染查询,分析大肠埃希菌对关键抗生素的耐药谱,并与MedQual社区监测系统及EARS-NET侵袭性感染监测网络比较。结果显示CDSS可实时提供社区获得性尿路感染耐药生态信息,在复杂性上尿路感染中提示经验性使用氟喹诺酮类的风险并建议优先使用第三代头孢菌素。
要点
- 共收集43591条尿路感染查询,其中10192条(23%)涉及大肠埃希菌。
- 大肠埃希菌对阿莫西林耐药率41.3%,低于MedQual的42.7%和EARS-NET的55.2%。
- 氟喹诺酮耐药率16.6%,高于MedQual的12.0%和EARS-NET的15.8%。
核心结论
- CDSS能够实时向处方者提供社区获得性尿路感染中大肠埃希菌耐药生态与监测信息。
- 在复杂性上尿路感染中,CDSS可强调经验性使用氟喹诺酮类的风险并建议优先使用第三代头孢菌素。
研究设计与样本
- 研究通过法国CDSS提交的尿路感染查询,收集2017至2020年涉及大肠埃希菌的尿路感染按类型划分的关键抗生素药敏谱。
- 将CDSS结果与MedQual法国社区获得性尿路感染监测系统及欧洲抗菌药物耐药监测网络(EARS-NET)侵袭性感染数据进行比较。
主要发现
- 共收集43591条尿路感染查询,其中10192条(23%)涉及大肠埃希菌:40%为膀胱炎,32%为男性尿路感染,27%为肾盂肾炎。
- 耐药率分别为阿莫西林41.3%(95%CI 40.3%-42.2%)、氟喹诺酮类16.6%(95%CI 15.9%-17.3%)、第三代头孢菌素6.6%(95%CI 6.1%-7.0%)、氨基糖苷类5.7%(95%CI 5.2%-6.1%)。
- 阿莫西林耐药率低于MedQual(42.7%,P=0.004)和EARS-NET(55.2%,P<0.001)。
- 氟喹诺酮类耐药率高于MedQual(12.0%,P<0.001)和EARS-NET(15.8%,P=0.041)。
- 复杂性肾盂肾炎和男性尿路感染中氟喹诺酮耐药率峰值约20%;第三代头孢菌素所有尿路感染耐药率高于MedQual(3.5%,P<0.001)但低于EARS-NET(9.5%,P<0.001);氨基糖苷类耐药率低于EARS-NET(7.1%,P<0.001),MedQual未报告该数据。
关键数值与推荐
- CDSS中大肠埃希菌对阿莫西林耐药率为41.3%(95%CI 40.3%-42.2%),低于MedQual的42.7%(P=0.004)和EARS-NET的55.2%(P<0.001)。
- CDSS中大肠埃希菌对氟喹诺酮类耐药率为16.6%(95%CI 15.9%-17.3%),高于MedQual的12.0%(P<0.001)和EARS-NET的15.8%(P=0.041)。
- CDSS中大肠埃希菌对第三代头孢菌素耐药率为6.6%(95%CI 6.1%-7.0%),高于MedQual的3.5%(P<0.001)但低于EARS-NET的9.5%(P<0.001)。
- CDSS中大肠埃希菌对氨基糖苷类耐药率为5.7%(95%CI 5.2%-6.1%),低于EARS-NET的7.1%(P<0.001),MedQual未报告该数据。
- 复杂性肾盂肾炎和男性尿路感染中氟喹诺酮耐药率峰值约20%。
临床怎么用
- CDSS可实时向处方者提供社区获得性尿路感染中大肠埃希菌耐药生态与监测信息。
- 在复杂性上尿路感染中,CDSS可强调经验性使用氟喹诺酮类的风险并建议优先使用第三代头孢菌素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital-based surveillance of antimicrobial resistance may be irrelevant as a guide to antimicrobial use for urinary tract infections (UTIs) in primary care. OBJECTIVES: To highlight the value of online computerized decision support systems (CDSS) in providing information on the surveillance of antimicrobial resistance in community-acquired UTIs. METHODS: We collected the susceptibility profile for key antibiotics by type of UTI involving Escherichia coli from 2017 to 2020, using queries for UTI (Q-UTI) submitted to a French CDSS. We compared these results with those from the MedQual French surveillance system for community-acquired UTI and the European Antimicrobial Resistance Surveillance Network (EARS-NET) for invasive infections. RESULTS: We collected 43 591 Q-UTI, of which 10 192 (23%) involved E. coli: 40% cystitis, 32% male-UTI, and 27% pyelonephritis. Resistance was 41.3% (95% CI, 40.3%-42.2%) for amoxicillin, 16.6% (95% CI, 15.9%-17.3%) for fluoroquinolones, 6.6% (95% CI, 6.1%-7.0%) for third-generation cephalosporins (3GC), and 5.7% (95% CI, 5.2%-6.1%) for aminoglycosides. Resistance to amoxicillin was lower than that reported in MedQual (42.7%, P value = 0.004), and in EARS-NET (55.2%, P value < 0.001). For fluoroquinolones, resistance was higher than in MedQual (12.0%, P value < 0.001) and EARS-NET (15.8%, P value = 0.041). In complicated pyelonephritis and male UTI, fluoroquinolone resistance peaked at ∼20%. For 3GC, all UTI had higher resistance than in MedQual (3.5%, P value < 0.001), but lower than in EARS-NET (9.5%, P value < 0.001). Aminoglycoside resistance was not reported by MedQual, and was lower than in EARS-NET (7.1%, P value < 0.001). CONCLUSIONS: CDSS can inform prescribers in real-time about the ecology and surveillance of E. coli resistance in community-acquired UTI. In complicated upper UTIs, they can underline the risk of empirical use of fluoroquinolones and suggest preferential use of 3GC.
引用
- Delory T, Le Bel J, Lariven S, et al. Computerized decision support system (CDSS) use for surveillance of antimicrobial resistance in urinary tract infections in primary care. J Antimicrob Chemother. 2022. PMID: 34747446. doi:10.1093/jac/dkab392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。